- Home
- PFLT vs TNGX Comparison
PFLT vs TNGX Comparison
Compare PFLT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFLT | TNGX |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 899.9M | 1.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PFLT | TNGX |
|---|---|---|
| Price | $9.32 | $11.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $10.75 | ★ $12.50 |
| AVG Volume (30 Days) | 954.8K | ★ 2.5M |
| Earning Date | 02-09-2026 | 02-26-2026 |
| Dividend Yield | ★ 13.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $261,427,000.00 | $66,501,000.00 |
| Revenue This Year | $11.66 | $52.80 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.19 | ★ N/A |
| Revenue Growth | 40.28 | ★ 53.29 |
| 52 Week Low | $8.40 | $1.03 |
| 52 Week High | $11.50 | $11.20 |
Technical Indicators
Market Signals| Indicator | PFLT | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 52.45 | 79.22 |
| Support Level | $9.01 | $8.66 |
| Resistance Level | $9.53 | $9.16 |
| Average True Range (ATR) | 0.14 | 0.62 |
| MACD | 0.02 | 0.22 |
| Stochastic Oscillator | 55.24 | 93.96 |
Price Performance
Historical ComparisonAbout PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate both current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generates revenue in the form of interest income on the debt securities and dividends.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.